OKEP Oct'15

1.

Name:

2.

Territory:

3.

Email Id:

4.

Pregabalin, a high affinity ligand of alpha-2-delta (α2-δ) subunits of voltage-gated calcium channels in the central nervous system, is considered a ____ drug for the treat-ment of NeP.

(a) First line

(b) Second line

(c) Adjunctive

(d) None

5.

In randomized clinical trials, pregabalin significantly improved patient-reported sleep disturbance across multiple conditions, through _____ analgesic effect and a _____ effect on sleep.

(a) Direct, Indirect

(b) Indirect, indirect

(c) Direct, Direct

(d) Indirect, Direct

6.

Sleep was used as the primary efficacy endpoint as has a ____ relationship with pain.

a) Direct. (a) Directlergic rhinitis and comorbid asthma and allergic rhinitis in patients 15 years of age

(b) Indirect

(c) Reciprocal

(d) Inverse

7.

Secondary endpoints included changes in pain and func¬tion from baseline to weeks ___

(a) 8 & 4

(b) 4 & 4

(c) 4 & 8

(d) 8 & 8

8.

Pregabalin resulted in significantly greater improvements, least-squares mean changes of ___ versus ___ for usual care.

(a) (P<0.001), (P = 0.012)

(b) -1.3, 0.4

(c) (P=0.012), (P<0.001)

(d) -0.4, 1.3

9.

In the context of CLBP, the most common syndrome is neuropathic pain (NeP) _____ to nerve root involvement.

(a) Primary

(b) Secondary

(c) Tertiary

(d) Quarterly

10.

Relative to usual care at week __, pregabalin improved pain and function (both P<0.001), and showed global improvements since beginning study medication (P<0.001).

(a) 5

(b) 7

(c) 9

(d) None

11.

LS mean changes from baseline were ___ and ___ for pregabalin and usual care, respectively.

(a) 1.1, -0.3

(b) -1.1, 0.3

(c) -1.1, 1.1

(d) 0.3, 1.1

12.

When LBP lasts for _____ it is known as chronic LBP (CLBP)

(a) ≥3

(b) ≥5

(c) ≥7

(d) ≥9